Stifel Nicolaus Has Lowered Expectations for Artivion (NYSE:AORT) Stock Price

Artivion (NYSE:AORT - Get Free Report) had its price target decreased by Stifel Nicolaus from $33.00 to $30.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Stifel Nicolaus' price target suggests a potential upside of 18.39% from the stock's current price.

Several other brokerages have also commented on AORT. Needham & Company LLC reduced their price objective on Artivion from $34.00 to $32.00 and set a "buy" rating on the stock in a research report on Tuesday. Oppenheimer increased their price target on shares of Artivion from $30.00 to $32.00 and gave the company an "outperform" rating in a research report on Friday, November 8th. Finally, JMP Securities restated a "market outperform" rating and issued a $33.00 price objective on shares of Artivion in a report on Tuesday, December 10th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $31.40.

Artivion Price Performance

Artivion stock traded down $0.02 during mid-day trading on Tuesday, hitting $25.34. 568,539 shares of the company traded hands, compared to its average volume of 404,014. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. Artivion has a one year low of $18.38 and a one year high of $32.33. The stock has a market cap of $1.06 billion, a price-to-earnings ratio of -1,267.00 and a beta of 1.75. The stock has a fifty day moving average price of $29.58 and a 200-day moving average price of $27.80.

Remove Ads

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.12 by ($0.51). The company had revenue of $97.31 million for the quarter, compared to the consensus estimate of $100.82 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. On average, equities analysts predict that Artivion will post 0.37 earnings per share for the current fiscal year.

Insider Activity at Artivion

In other Artivion news, VP Andrew M. Green sold 7,618 shares of the business's stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $30.00, for a total value of $228,540.00. Following the completion of the sale, the vice president now owns 33,503 shares in the company, valued at approximately $1,005,090. The trade was a 18.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Amy Horton sold 4,329 shares of the firm's stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $29.66, for a total transaction of $128,398.14. Following the completion of the transaction, the chief accounting officer now owns 135,660 shares in the company, valued at $4,023,675.60. This represents a 3.09 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 77,224 shares of company stock worth $2,162,330 in the last ninety days. 8.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Artivion

Hedge funds have recently modified their holdings of the company. Quarry LP boosted its holdings in shares of Artivion by 210.8% during the third quarter. Quarry LP now owns 1,209 shares of the company's stock worth $32,000 after purchasing an additional 820 shares during the period. Smartleaf Asset Management LLC raised its position in Artivion by 236.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company's stock valued at $32,000 after purchasing an additional 786 shares during the last quarter. R Squared Ltd purchased a new stake in Artivion in the 4th quarter worth approximately $39,000. Arcadia Investment Management Corp MI bought a new stake in shares of Artivion in the 4th quarter worth approximately $43,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Artivion during the fourth quarter valued at approximately $64,000. Hedge funds and other institutional investors own 86.37% of the company's stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.